Shares of Mylan N.V. MYL have gained 7.6% in the last three months, as against the industry’s decline of 3.7%. View photos Mylan’s fourth-quarter results were mixed with the bottom line exceeding expectations but the top line lagging …
Many argue the stock could be worth 20x EPS or more ... The drug will soon face generic competition, though generic manufacturer Mylan Inc. has thus far been …
Forbes1mon
10 stocks we like better than Mylan When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and …
Glatopa was developed under a collaboration agreement between MNTA and Sandoz and is produced in the US. …
Past EpiPen pricing litigation and other issues still keeping the stock price low. Post-announcement, MYL is undervalued, but is not a screaming buy if the price rebounds to pre-announcement levels. If the stock bounces back, we …
Mylan's EpiPen price hikes made it the face of corporate greed last summer. Now, the drug maker is lavishing a top exec with an eye-popping pay package. Despite the EpiPen scandal and a slumping stock price, Mylan (MYL) rewarded …
In total, 18 companies and two top executives, including Mylan's president, are now named in the complaint. Mylan's …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYL at https://www.zacks.com/ap/MYL